Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Duration Of Use In NSCLC May Increase Alongside Promotional Efforts

Executive Summary

Duration of use for Avastin in lung cancer may increase with continued promotion of the indication, according to Genentech

You may also be interested in...



Lucentis Faces Additional Pressure From NIH’s Avastin Trials

Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin

Lucentis Faces Additional Pressure From NIH’s Avastin Trials

Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin

Biogen/Elan Begin Promoting Tysabri Efficacy; Other JP Morgan Items In Brief

Tysabri marketing moves to efficacy: Biogen Idec/Elan are returning the marketing emphasis for the multiple sclerosis drug Tysabri (natalizumab) back to efficacy, after initially focusing on educating patients and physicians about the TOUCH risk management program and the risk of progressive multifocal leukoencephalopathy, Biogen Idec CEO Jim Mullen states. "It's been probably since we withdrew this product from the market in February 2005 [that] we've really discussed efficacy," he said. "That's the next phase of this launch, to really emphasize the important efficacy of this product." The firms relaunched Tysabri in June following FDA reapproval (1"The Pink Sheet" June 12, 2006, p. 5)...

Related Content

UsernamePublicRestriction

Register

PS047908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel